BN
|
HealthAI Desk•1 views

Novo Nordisk Shares Jump on UK Regulator's Wegovy Heart Health Nod

Novo Nordisk's stock rose following NICE's recommendation to use Wegovy for heart attack and stroke prevention on England's NHS. The drug, containing semaglutide, is now accessible to patients with prior cardiovascular events and a BMI of at least 27. This expands Wegovy's indication beyond weight loss and could enhance Novo Nordisk's market reach. Shares initially jumped 4% before stabilizing at a 2% increase. The decision underscores the growing role of GLP-1 agonists in comprehensive health management. This development is significant for the pharmaceutical and healthcare sectors.

Ad slot
Novo Nordisk Shares Jump on UK Regulator's Wegovy Heart Health Nod

Novo Nordisk's shares surged after England's drug price regulator recommended its weight-loss drug Wegovy for preventing heart attacks and strokes, expanding NHS access.

Market Reaction

  • Novo Nordisk shares rose up to 4% early, then pared gains to 2% in morning trading.
  • The broader Stoxx 600 European index was up 2.1%.

NICE Recommendation

  • The National Institute for Health and Care Excellence (NICE) endorsed semaglutide, Wegovy's active ingredient, for cardiovascular risk reduction.
  • This move significantly broadens Wegovy's use on the National Health Service (NHS).
Ad slot

Eligibility Criteria

The recommendation is for adults who meet all of the following:

  • History of heart attack, stroke, or serious circulation problem in the legs.
  • Body mass index (BMI) of at least 27.

Drug Context

  • Wegovy is primarily a weight-loss treatment but is also approved for reducing cardiovascular risks.
  • Semaglutide is the same compound used in Novo Nordisk's diabetes drug Ozempic.

Note

This is a breaking news story; please refresh for updates.

Ad slot